IsoAid has been awarded a three-year contract to provide members of the healthcare group purchasing organization Amerinet with its line of brachytherapy products, used primarily in the treatment of prostate cancer.

The agreement, which will begin on Oct. 1, offers Amerinet’s membership market pricing and access to IsoAid’s Advantage I-125 and Advantage Pd-103 seeds and related brachytherapy products, according to the Port Richey, Fla.-based IsoAid.